Full text is available at the source.
Regional trends and disparities in newer GLP1 receptor agonist initiation among real‐world adult patients eligible for obesity treatment
Differences across regions in starting new GLP-1 medicines among adults eligible for obesity treatment
AI simplified
Abstract
Only 1.8% of 319,949 adults initiated newer anti-obesity medications.
- Semaglutide was the most commonly initiated medication, accounting for 77.9% of all initiations.
- Liraglutide uptake peaked at 5% in 2018 but has since declined, while semaglutide and tirzepatide use has increased significantly since 2022.
- Lower initiation odds were observed in Black and Hispanic populations compared to White individuals.
- Medicaid and uninsured patients had lower initiation odds than those with private insurance.
- Higher initiation odds were associated with being female, middle-aged, more outpatient visits, and consultations with endocrinologists.
AI simplified